RenovoRx Highlights $563K Q1 RenovoCath Sales, Phase III Enrollment Closure
RenovoRx will present at the AGP Virtual Healthcare Company Showcase on May 20, with CEO Shaun Bagai and CFO Mark Voll highlighting record first-quarter 2026 RenovoCath revenue of $563,000 and accelerating adoption at high-volume cancer centers. The company expects to complete Phase III TIGeR-PaC trial enrollment by early June and deliver final data in mid to late 2027.
1. Presentation at AGP Virtual Showcase
RenovoRx’s CEO Shaun Bagai and CFO Mark Voll will speak at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20. They will outline recent commercial achievements and clinical program milestones during the 1:40 PM ET session.
2. Record RenovoCath Commercial Performance
The company reported a record $563,000 in RenovoCath standalone device sales for the first quarter of 2026, following approximately $1.1 million in sales during its first full commercial year in 2025. RenovoRx continues to drive adoption at high-volume National Cancer Institute-designated centers and secure growing repeat orders.
3. Progress in Phase III TIGeR-PaC Trial and IITs
Enrollment in the Phase III TIGeR-PaC trial of intra-arterial gemcitabine delivered via RenovoCath (IAG) is expected to close in early June, meeting the milestone of full enrollment by end of June 2026. Final data are anticipated in mid to late 2027, while investigator-initiated trials and post-marketing registry studies proceed to broaden the TAMP therapy platform’s application.